With growing cases of COVID-19, Pakistan has signed a pact Bangladeshi firm to supply a generic version of remdesivir — a broad-spectrum antiviral medication that has shown to lessen the recovery time in coronavirus patients, reports the Dawn.
The drug – remdesivir, has been permitted emergency use authorisation by the US Food and Drug Administration (FDA) and authorities in Japan and the UK to treat patients with severe signs of COVID-19.
According to a statement released by Searle Company Limited, Pakistan, the company has signed an exclusive pact with Beximco Pharmaceuticals, Bangladesh.
It’s the first firm in the world to introduce the generic variant of the drug. Our pact will provide an instant supply of the drug at an economical rate and will assist the medics to treat COVID-19 patients without any delay, said Mohammad Sajid, officials ar Searle.
Remdesivir is a direct-acting viral drug that represses viral RNA (Ribonucleic acid) synthesis. It is administrated intravenously and is approved for the treatment of hospitalized patients with severe COVID-19 infection – the Dawn report says.
Searle, Sajid said, was aggressively taking the matter with the government officials of Pakistan for required approvals and was positive that in the current pandemic, the authorities would treat this matter on an urgent basis to support the drug availability.
The report acknowledges that Bangladesh has made extraordinary progress in the pharmaceutical sector in recent years. Some Bangladesh-based pharmaceutical corporations, they said, were approved by the FDA and exported their products to the US.
Remdesivir is presently undergoing clinical trials around the world. Early research indicated it can cut recovery time by about four days, but so far there has been no concrete proof that it will save more lives.